Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.…
Graphique des rendements saisonniers Cellectis S.A. (ALCLS.PA)
Valerio Therapeutics (EPA: ALVIO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 41 employees.
The shares were at 0.3550 EUR on 20 November 2026, up 101.7% over 52 weeks. Its 52-week range is 0.1025 EUR to 0.9800 EUR: the price is 63.8% below the high and 246.3% above the low.
Its market capitalisation is 208.60M EUR.
Valerio Therapeutics reports return on equity of -236.0% and an operating margin of -50.4%.
Its debt exceeds its cash by 12.67M EUR, a debt-to-equity ratio of 3.67. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.
No upcoming events tracked.